





# Sulfadoxine + pyrimethamine

Essential medicine status 

Section: [6. Anti-infective medicines](#) > [6.5. Antiprotozoal medicines](#) > [6.5.3. Antimalarial medicines](#) > [6.5.3.1. Antimalarial medicines](#) > For curative treatment

	<b>EMLc</b>	ATC codes: <b>P01BD51</b>
Indication	Malaria due to Plasmodium falciparum	ICD11 code: <b>1F40</b>
INN	Sulfadoxine + pyrimethamine	
Medicine type	Chemical agent	
List type	Core (EML) (EMLc)	
Additional notes	Only in combination with artesunate 50 mg	
Formulations	Oral > Solid: 500 mg + 25 mg tablet	
EML status history	First added in 1979 ( <a href="#">TRS 641</a> ) Changed in 1987 ( <a href="#">TRS 770</a> ) Changed in 2003 ( <a href="#">TRS 920</a> ) Changed in 2007 ( <a href="#">TRS 946</a> ) Changed in 2007 ( <a href="#">TRS 950</a> )	
Sex	All	
Age	Also recommended for children	
Therapeutic alternatives	The recommendation is for this specific medicine	
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 	
Wikipedia	<a href="#">Sulfadoxine + pyrimethamine</a> 	
DrugBank	<a href="#">Sulfadoxine</a>  , <a href="#">Pyrimethamine</a> 	

## Summary of evidence and Expert Committee recommendations

Sulfadoxine + pyrimethamine tablets 500 mg + 25 mg was added to the EMLc for the curative treatment of malaria.

